PipelineReview.com14d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and datopotamab deruxtecan (Dato-DXd), a TROP2 directed ADC, which are being jointly developed and commercialized globally ...
Le Lézard14d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...
Yahoo Finance15d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 ...
precisionmedicineonline15d
AstraZeneca, Daiichi Sankyo Launch Three New Lung Cancer Trials of Dato-DXd
NEW YORK – AstraZeneca and Daiichi Sankyo on Wednesday said they have begun three new Phase III trials to test the activity of the Trop2-targeted antibody-drug conjugate datopotamab deruxtecan ...
Targeted Oncology17d
Continued Investigation of T-DXd Shows Promise in Breast Cancer
Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment. Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast ...